目的 观察益气消渴颗粒联合利拉鲁肽注射液治疗2型糖尿病的临床疗效。方法 选择天津中医药大学第一附属医院2022年3月—2024年1月收治的116例2型糖尿病患者，将患者按照随机数字表法分为对照组和治疗组，每组各58例。对照组皮下注射利拉鲁肽注射液，起始剂量0.6 mg/d，至少1周后剂量增加至1.2 mg/d，推荐剂量不超过1.8 mg/d。治疗组在对照组基础上开水冲服益气消渴颗粒，2袋/次，尿糖正常后1袋/次，3次/d。两组均治疗12周。比较两组的临床疗效、血糖指标、胰岛功能指标、血清炎症因子水平。结果 与对照组的总有效率77.59%相比，治疗组的总有效率93.10%明显更高（P＜0.05）。两组治疗后空腹血糖（FPG）、餐后2 h血糖（2 h PBG）、糖化血红蛋白（HbA1c）均降低（P＜0.05），治疗组治疗后FPG、2 h PG、HbA1c比对照组更低（P＜0.05）。两组治疗后胰岛β细胞功能指数（HOMA-β）升高，胰岛素抵抗指数（HOMA-IR）降低（P＜0.05），治疗组治疗后HOMA-β比对照组更高，HOMA-IR更低（P＜0.05）。两组治疗后血清白细胞介素-1β（IL-1β）、白细胞介素-8（IL-8）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）水平显著降低（P＜0.05），治疗组治疗后血清IL-1β、IL-8、CRP、TNF-α水平低于对照组（P＜0.05）。结论 益气消渴颗粒联合利拉鲁肽注射液治疗2型糖尿病可提高临床疗效，有效控制血糖水平和胰岛素功能，降低炎症因子水平。

Objective To observe the clinical efficacy of Yiqi Xiaoke Granules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus. Methods 116 Patients with type 2 diabetes mellitus admitted to First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from March 2022 to January 2024 were selected. The patients were divided into control group and treatment group using a random number table method, with 58 cases in each group. The control group received sc Liraglutide Injection, starting at 0.6 mg/d, increasing to 1.2 mg/d after at least one week, with a recommended dose not exceeding 1.8 mg/d. The treatment group was po administered with Yiqi Xiaoke Granules in addition to the control group's regimen, 2 bags/time, and 1 bag/time after urine glucose normalized, with 3 times daily. Two groups were treated for 12 weeks. Clinical efficacy, blood glucose indicators, pancreatic islet function indicators, and serum inflammatory factor levels were compared between two groups. Results Compared with the total effective rate of 77.59% in the control group, the total effective rate of 93.10% in the treatment group was significantly higher (P < 0.05). After treatment, FPG, 2 h PBG, and HbA1c in two groups decreased (P < 0.05). FPG, 2 h PG, and HbA1c in the treatment group were lower than those in the control group after treatment (P < 0.05). After treatment, HOMA-β increased, but HOMA-IR decreased in two groups (P < 0.05). The treatment group had higher HOMA-β and lower HOMA-IR than those in the control group after treatment (P< 0.05). After treatment, the serum levels of IL-1β, IL-8, CRP, and TNF-α were significantly reduced in two groups (P < 0.05). The serum levels of IL-1β, IL-8, CRP, and TNF-α in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion Yiqi Xiaoke Granule combined with Lilalutide Injection can improve the clinical efficacy of type 2 diabetes, effectively control the blood sugar level and insulin function, and reduce the level of inflammatory factors.

R976

天津市科技计划项目（20JCZXJC00060）